[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@iHooghvorst "@Jare92365776 Good finding 🫶. Its good to see progress on different partnerships through different routes papers published with gilead eli Lilly continuation abbvie new collab on tce spce and now this w vikings"
X Link @iHooghvorst 2025-10-13T06:09Z 3352 followers, XXX engagements

"@Algo_Stoney Bought some for Jan 2027 🫡"
X Link @iHooghvorst 2025-10-23T17:42Z 3366 followers, 1044 engagements

"With the amount of catalysts ahead I dont see this strategy going south for $abcl in the long term. Some that I can foresee: Novembers earnings call + X presentations during November-December. Gmp&cmc facility opening. Potential increase of revenue from older partnership efforts. Upfront payment from Abbvie collaboration on the TCE platform. Potential settlement with bruker for the microfluidic patent with possible compensation. Abcl635 & XXX readouts next year. 1-2 new molecules to IND a year. Potential partnering of abcl575 for bsAb or combo in clinic. New contracts for gmp manufacturing"
X Link @iHooghvorst 2025-10-24T07:26Z 3366 followers, 10.4K engagements

"@MartinShkreli never gave his opinion lately on $abcl as far as I am concern. He has a video on youtube analyzing the stock X year ago before abcl575 and XXX were out. He doesn't give much insight besides "abcl is a tech company or a biotech company" and "something is going to go right for this guys eventually". I wouldn't get too spooked about biotech investors hating abcl. AbCellera's valuation is high for a biotech but it is low for a tech company. The skeptics target abcl molecules and claim overvaluation I am focused on their tech for now. With time we will be able to judge their"
X Link @iHooghvorst 2025-10-16T09:05Z 3362 followers, 2366 engagements

"Hot take on $ABCL's XXX after the disappointing XX% placebo-adjusted remission rate for Sanofi's amlitelimab in its Phase X COAST-1 trial. Both molecules target the early OX40L checkpoint for inflammation in AtD. $SNY's results are encouraging in terms of MoA validation but weren't quite up to the expectations set by Dupixent (27% remission at Week XX in CHRONOS). AbCelleras molecule has an engineered Fc that provides an extended half-life alongside Fc silencing. This could translate to less frequent dosing and more consistent blockade of OX40L potentially resulting in improved remission"
X Link @iHooghvorst 2025-10-22T11:47Z 3366 followers, 5383 engagements

"@gimgyujin16822 Can you develop on that"
X Link @iHooghvorst 2025-10-24T09:49Z 3366 followers, XXX engagements